UNIQURE N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.07 USD | +0.20% |
|
0.00% | -25.11% |
| May. 08 | Mizuho Adjusts uniQure's Price Target to $6 From $7, Keeps Neutral Rating | MT |
| May. 07 | UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 47.23M 51.22M | Sales 2025 * | 83.38M 90.42M | Capitalization | 226M 245M |
|---|---|---|---|---|---|
| Net income 2024 * | -220M -239M | Net income 2025 * | -171M -185M | EV / Sales 2024 * | 3.32 x |
| Net cash position 2024 * | 69.35M 75.21M | Net Debt 2025 * | 9.03M 9.79M | EV / Sales 2025 * | 2.82 x |
| P/E ratio 2024 * |
-1.08
x | P/E ratio 2025 * |
-1.36
x | Employees | 480 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.72% |
More Fundamentals
* Assessed data
More news
Latest transcript on uniQure N.V.
More recommendations
More press releases
| 1 day | +0.20% | ||
| Current month | +14.97% | ||
| 1 month | +7.87% | ||
| 3 months | -13.33% | ||
| 6 months | -21.15% | ||
| Current year | -25.11% |
1 week
4.84
5.18
1 month
4.255.19
Current year
4.257.12
1 year
4.2521.88
3 years
4.2538.80
5 years
4.2582.49
10 years
4.2582.49
| Managers | Title | Age | Since |
|---|---|---|---|
Matt Kapusta
CEO | Chief Executive Officer | 51 | 14-12-31 |
Christian Klemt
DFI | Director of Finance/CFO | 51 | 14-12-31 |
Pierre Caloz
COO | Chief Operating Officer | 52 | 21-05-16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leonard Post
BRD | Director/Board Member | 72 | 20-06-16 |
Jack Kaye
BRD | Director/Board Member | 80 | 16-06-14 |
| Director/Board Member | 61 | 17-09-13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.96% | 11 M€ | -6.03% | - | |
| 0.76% | 14 M€ | -2.69% | ||
| 0.48% | 28 M€ | -0.39% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 5.07 | +0.20% | 347,654 |
| 24-05-15 | 5.06 | +3.05% | 462,888 |
| 24-05-14 | 4.91 | +0.61% | 431,769 |
| 24-05-13 | 4.88 | -0.81% | 410,147 |
| 24-05-10 | 4.92 | -2.96% | 730,215 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotes
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Companyâs lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntingtonâs disease is in Phase I/II clinical study.
Calendar
2024-06-18
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
4.664
EUR
Average target price
18.07
EUR
Spread / Average Target
+287.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -25.11% | 246M | |
| +8.29% | 114B | |
| +10.21% | 104B | |
| -11.90% | 22.41B | |
| +0.41% | 22.28B | |
| -5.52% | 19.07B | |
| -37.36% | 18B | |
| -5.17% | 17.89B | |
| +7.70% | 14.28B | |
| +37.65% | 12.55B |
- Stock Market
- Equities
- QURE Stock
